References
- 1. C. W. Oakley, Primary pulmonary hypertension. Case series from the United Kingdom, Chest. 105 (1994) 29S-32S; DOI: 10.1378/chest.105.2_Supplement.29S.
- 2. B. G. Schwartz, L. A. Levine, G. Comstock, V. J. Stecher and R. A. Kloner, Cardiac uses of Phosphodiesterase-5 Inhibitors, JACC 59 (2012) 9-15; DOI:10.1016/j.jacc.2011.07.051.
- 3. G. D. Lewis, R. Shah, K. Shahzad, J. M. Camuso, P. P. Pappagianopoulos, J. Hung, A. Tawakol, R. E. Gerszten, D. M. Systrom, K. D. Bloch, M. J. Semigran, Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension, Circulation 116 (2007) 1555-1562; DOI: 10.1161/CIRCULATIONAHA.107.716373.
- 4. V. Q. Chau, F. N. Salloum, N. N. Hoke, A. Abbate and R. C. Kukreja, Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway, Am. J. Physiol. Heart Circ. Physiol. 300 (2011) H2272-H2279; DOI: 10.1152/ajpheart.00654.2010.
- 5. J. Nagendran, S. L. Archer, D. Soliman, V. Gurtu, R. Moudgil, A. Haromy, C. St Aubin, L. Webster, I. M. Rebeyka, D. B. Ross, P. E. Light, J. R. Dyck, E. D. Michelakis, Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility, Circulation 116 (2007) 238-248; DOI: 10.1161/CIRCULATIONAHA. 106.655266.
- 6. L. Zhao, N. A. Mason, N. W. Morrell, B. Kojonazarov, A. Sadykov, A. Maripov, M. M. Mirrakhimov, A. Aldashev and M. R. Wilkins, Sildenafil inhibits hypoxia-induced pulmonary hypertension, Circulation 104 (2001) 424-428; DOI: 10.1161/hc2901.093117.
- 7. P. Rajagopalan, A. Mazzu, C. Xia, R. Dawkins and P. Sundaresan, Effect of high-fat breakfast and moderate-fat evening meal on pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, J. Clin. Pharmacol. 43 (2003) 260-267; DOI: 10.1177/0091270002250604.
- 8. A. H. Elshafeey, E. R. Bendasand O. H. Mohamed, Intranasal microemulsion of sildenafil citrate: in vitro evaluation and invivo pharmacokinetic study in rabbits, AAPSPharmSciTech. 10 (2009) 361-367; DOI: 10.1208/s12249-009-9213-6.
- 9. A. H. Shajaei, Buccal mucosa as a route for systemic drug delivery. J. Pharm. Pharmaceut. Sci. 1 (1998) 15-30; http://www.ualberta.ca/~csps/JPPS1(1)/A.Shojaei/buccalreview.htm.
- 10. Z. Bayrak, C. Tas, U. Tasdemir, H. Erol, C. K. Ozkan, A. Sayaser and Y. Ozkan, Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation, Eur. J.Parm. Biopharm. 78 (2011) 499-505; DOI: 10.1016/j.ejpb.2011.02.014.
- 11. S. A. Randale, C. S. Dabhi, A. R. Tekade, V. S. Belgamwar, S. G. Gattani and S. J. Surana, Rapidly disintegrating tablets containing taste masked metoclopramide hydrochloride prepared by extrusion-precipitation method, Chem.Pharm. Bull, 58 (2010) 443-448; DOI: 10.1248/cpb.58.443.
- 12. S. Bandari, R. K. Mittapalli, R.Gannu and Y. H. Rao, Orodispersibletablets: an overview, Asian J. Pharm. 2 (2008) 2-11; DOI: 10.4103/0973-8398.41557.
- 13. G. Abdelbary, C. Eouani, P. Prinderre, J. Joachim, J. Reynier and P. Piccerelle, Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration, Int. J. Pharm. 292 (2005) 29-41; DOI:10.1016/j.ijpharm.2004.08.019.
- 14. J. W. Moore and H. H. Flanner, Mathematical comparison of dissolution profiles, Pharmaceutical Technology, 20 (1996) 64-74.
- 15. »Declaration of Helsinki.« As amended by the 59th World Medical Assembly (WMA). World Medical Association, Seoul, South Korea, October 2008. Available at: http://www.wma.net/e/ethicsunit/helsinki.htm.
- 16. V. P. Shah, K. K. Midha, S. Dighe, I. J. McGilveray, J. P. Skelly, A. Yacobi, T. Layloff, C. T. Viswanathan, C. E. Cook and R. D. McDowall, Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report, Eur. J. Drug Metab. Pharmacokinet. 16 (1991) 249-255; DOI: 10.1002/jps.2600810324.
- 17. A. P. Simonelli, S. C. Mehta, W. I. Higuchi. Dissolution rates of high energy polyvinylpyrrolidone-sulfathiazole coprecipitates, J. Pharm. Sci. 58 (1969) 538-549; DOI: 10.1002/jps.2600580503.
- 18. O. I. Corrigan, Mechanisms of dissolution of fast release solid dispersions. Drug Dev. Ind. Pharm. 11 (1985) 697-724; DOI: 10.3109/03639048509056896.
- 19. M. Newa, K. H. Bhandari, D. X. Li, T. H. Kwon, J. A. Kim, B. K. Yoo, J. S. Woo, W. S. Lyoo, C. S. Yong, H. G. Choi, Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with Poloxamer 188, Int. J. Pharm. 343 (2007) 228-237; DOI: 10.1016/j.ijpharm.2007. 05.031.
- 20. N. Passerini, M. L. Gonzalez-Rodriguez, C. Cavallari, L. Rodriguez and B. Albertini, Preparation and characterisation of ibuprofen-poloxamer 188 granules obtained by melt granulation, Eur. J. Pharm. Sci. 15 (2002) 71-78; DOI: 10.1016/S0928-0987(01)00210-X.
- 21. P. P. Shah and R. C. Mashru, Development and evaluation of artemether taste masked rapid disintegrating tablets with improved dissolution using solid dispersion technique. AAPS Pharm.
- Sci. Tech. 9 (2008) 494-500; DOI: 10.1208/s12249-008-9066-4. 22. S. Khan, H. Batchelor, P. Hanson, Y. Perrie and A. R. Mohammed, Physicochemical characterization, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000, J. Pharm. Sci. 100 (2011) 4281-4294; DOI: 10.1002/jps.22613.
- 23. A. Quadir and K. Kolter, A comparative study of current superdisintegrants, Pharma. Tech. Com. 2006.
- 24. R. Chandrasekhar, Z. Hassan, F. Alhusban, A. M. Smith and A. R. Mohammed, The role of formulation excipients in the development of lyophilized fast-disintegrating tablets, Eur. J.Parm. Biopharm.72 (2009) 119-129; DOI: 10.1016/j.ejpb.2008.11.011.
- 25. W. L. Chiou and S. Riegelman, Pharmaceutical application of solid dispersion system, J. Pharm. Sci. 60 (1971) 1281-1302; DOI: 10.1002/jps.2600600902.
- 26. R. A. Shoukri, I. S. Ahmed and R. N. Shamma, In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets, Eur. J.Parm. Biopharm.73 (2009) 162-171; DOI: 10.1016/j.ejpb.2009.04.005.
- 27. V. B. Djagny, Z. Wang and S. Xu, Gelatin: A valuable protein for food and pharmaceutical industries: Review, Crit. Rev. Food Sci. Nutr.41 (2001) 481-492; DOI: 10.1080/20014091091904.
- 28. P. J. Dawson and D. J. Hockley, Scanning electron microscopy of freeze-dried preparations: relationship of morphology to freeze-drying parameters, Develop. Biol.Standard. 74 (1991) 185-192.
- 29. D. J. van Drooge, W. L. J. Hinrichs and H. W. Frijlink, Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvent, J. Pharm. Sci.93 (2004) 713-725; DOI: 10.1002/jps.10590.
- 30. A. A. Mahmoud and S. Salah, Fast relief from migraine attacks using fast-disintegrating sublingual zolmitriptan tablets, Drug Dev. Ind. Pharm. (2011) 1-8; DOI:10.3109/03639045.2011.625949.
- 31. REVATIO - sildenafil citrate tablet, film coatedPfizer Labs http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfmfiarchiveid=10206.
- 32. A. Abdelbary, A. H. Elshafeeyand G. Zidan, Comparative effects of different cellulosic-based directly compressed orodispersable tablets on oral bioavailability of famotidine, Carb. Polym. 77 (2009) 799-806; DOI:10.1016/j.carbpol.2009.02.030.
- 33. M. M. Rawas-Qalaji, F. E. Simons and K. J.Simons, Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis, J. Allergy Clin. Immunol. 117 (2006) 398-403; DOI:10.1016/j.jaci.2005.12.1310.
- 34. G. V. Betageri and K. R. Makarla, Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques, Int. J. Pharm. 126 (1995) 155-160; DOI: 10.1016/0378-5173(95) 04114-1.